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CHANGES IN ESTROGEN RECEPTOR ALPHA (ERα) PHOSPHORYLATION IN HUMAN T CELLS

An Abstract of the Thesis by
Samantha Meneely

Estrogen has two receptor proteins, estrogen receptor alpha (ERα) and estrogen
receptor beta (ERβ). ERα can undergo multiple post-transcriptional modifications
(PTMs); however, relatively little is known about the function and regulation of any of
the PTMs that ERα can potentially undergo, especially in vivo. In total, 19
phosphorylation sites have been identified in ERα thus far, and most sites contain a SerPro motif. Different pathways are responsible for the phosphorylation of different sites.
These pathways include mitogen-activated protein kinase (MAPK) signaling, IkappaB
kinase complex alpha (IKKα), cyclin-dependent kinase 7 (CDK7), a subunit of
transcription factor II H, protein kinase B (PKB), glycogen synthesis kinase-3 beta
(GSK3β), mammalian target of rapamycin (mTOR/p70S6K), ribosomal s6 kinase (Rsk),
and casein kinase II. Here, phosphorylation of three sites between resting and activated
human T cells are compared. T cells were purified and total proteins were extracted
from both resting and activated T cells. Changes in ERα were investigated via
immunoprecipitation and Western blot. The amount of phosphorylation at each site was
compared between resting and activated T cells, and the amount of phosphorylated
receptor was adjusted to the total ERα in each sample. The results for a sample size of
ten indicated that when ERα is at 100%, Ser 104/106 resting T cells are 89.30% and
active are 92.00%, Ser 118 resting T cells are 80.08% and activated are 87.54%, and Ser
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167 resting T cells are 86.44% and activated are 78.35%. Statistical analysis revealed the
results were significant for both resting and activated T cell for ERα Ser 118 and Ser 167,
but not for Ser 104/106 in those same conditions. These results provide a baseline for
studying the phosphorylation changes in SLE patients. It is known that the MAPKERK1/2 pathway is abnormal in SLE; therefore, it is hypothesized there will be a
decrease in phosphorylation in activated T cells compared with control.
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CHAPTER I

INTRODUCTION

Estrogen and its Receptors

Estrogen, a class of female steroid hormones, induces cellular changes to
different mechanisms throughout the body (1). The systems include the bone, brain,
uterus, breast tissue, ovaries, heart, and fat (1). The hormone serves as a ligand for two
specific receptor proteins termed estrogen receptor alpha (ERα) and estrogen receptor
beta (ERβ) (2). These nuclear receptor complexes are dynamic transcription factors that
can shuttle between the cytoplasm and nucleus in order to bind to specific DNA
sequences of target genes and alter transcription rates (3, 4, 5). ERα and ERβ bind
estradiol, a type of estrogen, with equal affinity, and both receptor subtypes interact
with the estrogen-response element (ERE), an inverted-repeat DNA sequence found in
the promoter regions of many estrogen-responsive genes and regulates the expression
of ER-dependent genes (4, 5). Dimerization of the ER is required for transcriptional
activity and in cells that express both receptor subtypes ERα and ERβ, can form
heterodimers (5). ERα is unusual among nuclear hormone receptors, in that its turn-over
rate is more rapid than other nuclear receptors with a half-life of approximately 4 hours
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in breast cancer cells and in normal target tissues such as the uterus, indicating dynamic
regulation by modulating factors (6, 7, 8, 9). In contrast, ERβ has a half-life of 8 hours
and is predominately expressed in glanulosa cell-derived tissues, and to the lesser
extent in mucinous tissue of epithelial origin (1, 10, 11).
Steroid receptors (SR) share a common structure of a carboxyl-terminal ligand
binding domain (LBD) and an amino-terminal domain (NTD) (3) (Appendix A). The LBD is
linked by a hinge region (H) to a highly conserved DNA-binding domain (DBD),
comprising the hormone response element, and contains a hormone-dependent
coactivator interface called activation function 2 (AF2) (3). Coactivators have a common
signature motif, LXXLL, with which they can interact with ERα in a hormone dependent
manner (4, 12). Crystallography shows that, when an antagonist, such as tamoxifen,
binds to the LBD, helix 12 itself occupies the coactivator binding site, rendering ERα
inactive (4, 13, 14, 15). In contrast, the NTD contains a hormone-independent
coactivator interface AF1 (3). In a nonligand-bound state, helix 12 is highly mobile, and
upon binding of an agonist it takes a more fixed position, stabilizing the conformation of
ERα. Coactivators also bind to the AF1 domain of ERα, in a ligand-independent manner
(4). Structural changes of ER can influence coregulator binding and hence potentially the
response to ligands (4). However, in the presence of hormone antagonists, the ER
undergoes a conformational change that facilitates co-repressor binding (5). The
balance between activators and repressors may be a key concept for understanding the
ER-regulated gene expression (5).
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The NTD contains the majority of phosphorylation sites, which are
phosphorylated by a wide range of kinases (2, 3, 16). Many of these sites identified in
receptors isolated from hormone-treated cells contain serine-proline motifs (Ser-Pro)
which can be recognized by the peptidyl prolyl isomerase (Pin1), which facilitates in
protein folding (2, 3, 16). Net phosphorylation of the receptors also increases in
response to hormone (2). Thus, in addition to inherent change of charge,
phosphorylation of these sites can result in the isomerization and subsequent alteration
of receptor structure (3).
Receptors respond differently in the presence or absence of hormones. For
instance, ERα is predominantly nuclear in the absence of hormone, whereas in response
to hormone treatment it undergoes nuclear localization (2). Without the hormone,
several of the nuclear receptors, including the ER, are unable to bind to corepressors (5).
In the classical mechanism of estrogen action, estrogens diffuse into the cell and bind to
the receptor, which is located in the nucleus. This nuclear estrogen-ER complex binds to
the ERE sequences directly or indirectly through protein-protein interactions with
activator protein 1 (AP1) or specificity protein 1 (SP1) sites in the promoter region of
estrogen-responsive genes, resulting in recruitment of coregulatory proteins to the
promoters, increased or decreased mRNA levels and associated protein production, and
a physiological response (1). This classical, or genomic, mechanism typically occurs over
the course of hours. In contrast, estrogen can act more quickly (within seconds or
minutes) via nongenomic mechanisms through other non-ER plasma membrane-

~3~

associated estrogen-binding proteins, resulting in cellular responses such as increased
levels of Ca2+ or nitric oxide (NO), and activation of kinases (1).

Phosphorylation and Cell Signaling

SRs and their associated cofactors can be phosphorylated on multiple sites by a
wide range of kinases, which regulate various functions such as protein stability,
hormone sensitivity, DNA binding, subcellular localization, and protein interactions (3).
These functions can determine the timing, specificity, and extent of SR target gene
regulation (3). The specific response of SRs to the cognate ligands is largely influenced
by the cellular context including the levels of active kinases and phosphatases in
addition (3, 17, 18). Thus, at least some aspects of tissue specific actions of SRs are
controlled by cell signaling pathways (3).
SRs exhibit an increase in receptor phosphorylation and, in the classical pathway,
form homodimers that bind to response elements on DNA and recruit a series of
coactivator complexes that modify chromatin to facilitate transcription of target genes
(3). Although the majority of identified phosphorylation sites are serines (Ser), a few
threonines (Thr) and tyrosines (Tyr) also have been identified (3) (Appendix B). In
general, phosphorylation of serine residues in the AF1 domain of ERα appears to
influence the recruitment of coactivators, resulting in enhanced ER-mediated
transcription (19). Phosphorylation of sites within or outside the AF1 region may affect
the AFα dependent binding of cofactors as well (4). Site-specific SR phosphorylation has
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been studied extensively in ERα and to a lesser extent in ERβ (3). In the case of the ER,
ER-mediated gene transcription is tissue and cell-specific and can be coordinately
regulated by nongenomic signaling (5). In total, 19 phosphorylation sites have been
identified in ERα thus far, and most sites contain a Ser-Pro motif (3, 4). This however, is
not the case for Ser 167, which does not reside in a Ser-Pro motif (4).
There is the potential that phosphorylation not only causes a change in charge,
but results in isomerization of the peptide bond, substantially altering receptor
structure (2). Phosphorylation of the ER may change the three-dimensional structure of
the protein. Unfortunately, thus far no full-length ERα has been crystalized (4). Due to
the inability to study the crystalized structure, it is complicated to characterize the
structural changes upon ligand binding or PTMs, such as phosphorylation (4).
Furthermore, a conformational change due to phosphorylation could have
consequences for the action of estrogens and antiestrogens (4).
In addition to phosphorylation, ERα can undergo other PTMs, which include
acetylation, ubiquitination, and sumoylation (20, 21). However, relatively little is known
about the function and regulation of any of the PTMs that ERα can potentially undergo
and even less is known about their relevance in vivo (20). Phosphorylation plays a major
role in the regulation of receptor stability, although the mechanisms for regulation
appear to be receptor specific (2). Multifaceted mechanisms underlying estrogen action
have been identified, including: multiple ERs and variants; multiple subcellular
localization sites; multiple transcription coactivators and corepressors; multiple PTMs;
multiple levels of cross talk with other signaling pathways; and multiple levels of control
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of ER expression, including proteasomal-mediated degradation (20). Nevertheless, the
studies support the idea that specific phosphorylation events within SRs can influence
receptor localization, stability, dimerization, and transcriptional activity (3). The
phosphorylation of ERα can affect DNA binding, for example, by inhibiting dimerization
of the receptor, and can influence ERα activity by changing the binding of coactivators
or the orientation of components of the transcription factor complex (4).
Most of the phosphorylation changes studied to date have been done in breast
cancer, especially in the resistance to tamoxifen. The three sites studied in this research
project were Serine 104/106 (Ser 104/106), Serine 118 (Ser 118), and Serine 167 (Ser
167). Interestingly, within the A/B domain of ERα, often only small effects on
transcriptional function were observed when one site, e.g. Ser 104, Ser 106, and Ser 118
was mutated to eliminate phosphorylation (20, 22). The results illustrated that when the
three sites were mutated, they appeared to be additive, giving an approximately 50%
reduction in transcriptional activity (20). This showed that combinations of
phosphorylation sites affected activity more than individual sites alone (20, 23, 24).
Additionally, and more importantly, lack of phosphorylation of all of these sites does not
eliminate estrogen-induced ERα transcriptional activity (20). Furthermore, other data
suggests that it is the combination of phosphorylation sites within ERα rather than any
one individual site that may be important for mediating effects of any individual kinase
(20). This concept illustrates that combinations of PTMs of ERα rather than individual
sites may be of primary importance in affecting function and response to endocrine
therapies is emerging (20, 25, 26).
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Ser 118 is one of the most reported phosphorylation sites of ERα, in part because
phosphorylation of this site causes reduction in mobility of SDS-PAGE gels, and thus the
level of phosphorylation at this site could be detected before the development of site
specific phosphoantibodies (3, 4). Phosphorylation, at least at Ser 118, has been
suggested to be involved in protein turnover via a proteasome-mediated mechanism
(20, 27, 28). However, proteasome-mediated turnover of steroid receptors has been
shown to be essential for the dynamic and cyclical nature of receptor occupancy on
target gene promoters, which is in turn critically important for transcriptional activity
(20, 29).
Different pathways are responsible for the phosphorylation of different sites.
Estrogen induces mitogen-activated protein kinases (MAPK) signaling, which is essential
for cell proliferation (5). Ser 118 primarily deals with the MAPK-ERK1/2 pathway, an
important enzyme activated by growth factor receptor pathways, which can
phosphorylate Ser 118 in a ligand-independent manner in vitro and in vivo (20, 23, 30).
Ser 118 phosphorylation by MAPK-ERK1/2 increases binding of coactivator SRC3 and
renders ERα hypersensitive to estrogen (4, 31, 32). This occurs upstream of the
receptor, where the MAPK-ERK1/2 pathway can be activated by insulin-like growth
factor (IGF) stimulation. This activation induces the phosphorylation of ERα Ser 118 and
results in ERα activation and enhanced response to estrogen (4). Likewise, estrogen and
epidermal growth factor (EGF) can induce the extracellular signal-regulated kinase 1 and
2 (MAPK-ERK1/2) pathway, which also leads to Ser 118 phosphorylation of ERα (4).
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Interestingly, estrogen treatment is the most powerful stimulator of phosphorylation at
Ser 118 and it is independent of MAPK-ERK1/2 (20, 35).
Furthermore, the Ser 118 site has been shown to be important for the direct
binding to and activation/repression of a subset of endogenous ERα target genes (3). In
addition to target gene induction, Ser 118 has been reported to be important for both
ligand-dependent dimerization of ERα and ERα-mediated RNA splicing (3). While MAPKERK1/2 is the most common pathway, phosphorylation of Ser 118 can also occur
through IkappaB kinase complex alpha (IKKα), cyclin-dependent kinase 7 (CDK7), a
subunit of transcription factor II H, protein kinase B (PKB, which is also induced by EGF
and IGF), and glycogen synthesis kinase-3 beta (GSK3β), which stabilizes ERα without
ligand and modulates ERα transcriptional activity upon ligand binding (4, 19, 30, 33, 34,
35). This is especially common in breast cancer cell lines where there is a resistance to
tamoxifen; however, the clinical relevance of Ser 118 in its resistance to tamoxifen is still
unresolved (4).
Phosphorylation of Ser 118 affects the binding of coactivators in the presence of
tamoxifen, which reduces binding to DNA when ERα is tamoxifen bound, decreasing the
affinity for tamoxifen (4, 36). When Ser 118 was phosphorylated in a tamoxifen-resistant
cell line, MAPK-ERK1/2 activity was found to be elevated and phosphorylation of Ser 118
was increased (4, 32). Activation of the MAPK-ERK1/2 pathway results in Ser 118
phosphorylation, but it also induces a bypassing of the ER pathway, thereby rendering
tumors hormone-independent (4). Phosphorylation of Ser 118 has been associated with
a more differentiated phenotype, good prognosis, and better response to tamoxifen,
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which is supported by other studies (4, 37). Most importantly, these studies reported
that the Ser 118 phosphorylation had no effect on the progression of disease or survival
without tamoxifen treatment, thereby emphasizing that Ser 118 phosphorylation is a
clear predictive marker for response to tamoxifen in these studies (4).
The predictive and prognostic value of phosphorylated Ser 118 was assessed in a
randomized controlled trial of no systemic treatment versus two years of adjuvant
tamoxifen therapy (20, 37). Improved recurrence-free survival was found in those
patients whose tumors expressed high levels of phosphorylated Ser 118 (20, 38). In
addition, there are data to support the view that combinations of phosphorylated Ser
118 with known biologically relevant biomarkers such as progesterone receptors (PR)
may further improve the prediction of prognosis and response to endocrine therapy (20,
38). Such data supports the combined use of biologically relevant markers for the
improved prediction of therapy response (20, 38).
Like Ser 118, Ser 167 is phosphorylated by MAPK-ERK1/2 and PKB (4, 19, 39, 40).
In addition, it is also phosphorylated by protein 90 ribosomal s6 kinase (p90Rsk),
mammalian target of rapamycin (mTOR/p70S6K), ribosomal s6 kinase (Rsk), and casein
kinase II, upon estrogen binding of ERα (19, 4, 39, 40, 41). In the case of casein kinase II,
it has been suggested that ligand-bound ERα undergoes a conformational change that
exposes the Ser 167, making this residue available for phosphorylation (3).
Overexpression of the epidermal growth factor receptor (EGFR) induces Ser 167
phosphorylation, increases binding of ERα to DNA, enhances the binding of coactivator
SRC3 to ERα in the presence of estrogen, and consequently enhances transcription (4).
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Increased phosphorylation at Ser 167 via PKB has been associated with poor
clinical outcome in breast cancer patients treated with tamoxifen, with high risk for
relapse and decreased overall survival, which would imply that phosphorylation of Ser
167 is associated with a worse disease outcome (4, 19, 20, 42). Comparing the levels of
phosphorylated Ser 118 and 167 expression in primary breast tumors related to
secondary tumors from 10 patients after relapse, a study found that there was
increased levels of both phosphorylated Ser 118 and 167 on the secondary versus the
primary tumors, although this was statistically significant only for phosphorylated Ser
118 (20, 42). This corresponds with the research performed on a set of 75 primary
breast carcinomas of patients with metastatic breast cancer who received first-line
endocrine treatment after relapse, and those staining high for phosphorylated Ser 167
relapsed later (4). This statistic changed with endocrine treatment, where metastases
responded well to endocrine treatment and phosphorylated Ser 167 correlated with
longer survival after relapse (4). This implies that phosphorylation of Ser 167 is a
predictive marker for a good response to endocrine therapy (4).
Furthermore, in contrast to what would have been expected from laboratory
model systems, higher expression of either phosphorylated Ser 167 and/or Ser 118 is
most often, but not always, associated with a better clinical outcome in patients on
tamoxifen therapy (20, 38, 42, 43). High levels of phosphorylation for Ser 167 expression
is the better predictor of benefit from tamoxifen and also suggests that both of these
phosphorylation sites either alone or in combination in primary breast tumors may be
useful biomarkers of endocrine therapy response (19, 20). Either phosphorylated Ser
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118 or Ser 167 were found to be associated with the parameters of less aggressive and
more differentiated tumors as well as an intact estrogen-responsive signaling pathway
(20). Moreover, in vitro, phosphorylated Ser 167 reduces sensitivity to tamoxifen,
keeping in mind that clinical data of Ser 167 phosphorylation are conflicting (4).
Tamoxifen resistance has been associated with several kinase pathways,
which occurs upstream of ERα (4). Pathways include activation of the protein kinase A
(PKA), MAPK-ERK1/2, GSK-3, IKKα, CDK7, mTOR/p70S6K, and p21-activated kinase 1
(PAK-1) signaling pathways (4). These kinases induce phosphorylation of ERα or of its
coregulators (4). Dependent on the pathway and the phosphorylation sites involved,
tamoxifen response can be affected either directly through ERα modification or by
activation of other signaling pathways (4). Phosphorylation of Ser 118 is described as an
example of this: an activated MAPK-ERK1/2 pathway phosphorylates Ser 118, but
possibly induces tamoxifen resistance through the MAPK-ERK1/2 pathway itself, rather
than ER signaling (4).
A third site that known to be resistant to tamoxifen is Ser 104/106. This site is
also phosphorylated by ERα and signaling pathways. Most functional studies of Ser
104/106 have also included the Ser 118 site (4). Serine residues 102, 104, and 106 at the
N-terminal AF1 of ERα are phosphorylated by GSK-3 and MAPK-ERK1/2 pathways (4).
These modifications lead to ligand-independent transcription of ERα and to an agonistic
activity of tamoxifen (4). Ser 104 and Ser 106 can also be phosphorylated by the
CDK2/cyclin A complex; and cyclin A has been reported as a predictive marker for
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tamoxifen resistance in breast cancer patients (4, 44). Because of this, tamoxifen
resistance is likely to occur when Ser 104/106 is phosphorylated (4).

Abnormalities- Breast Cancer

Estrogen and phosphorylation of the three sites (Ser 104/106, Ser 118, and Ser
167) has been studied most extensively in ER-positive breast cancer. ERα is the main
target of endocrine therapies because the nuclear hormone receptor is a master
regulator of gene expression and proliferative of breast cancer cells (6). Approximately
70% of human breast tumors express ERα and depend on estrogen for growth;
therefore, endocrine therapy has become the most important treatment option for
women with ER-positive breast cancer (6, 19). Advanced-stage breast cancers often lack
SRs and/or are resistant to endocrine therapies (45). PRs are key markers for steroid
hormone dependence and indicators of disease prognosis in breast cancer; their loss
signals development of the aggressive tumor prototype associated with acquisition of
enhanced sensitivity to growth factors (45, 46, 47). Many breast cancer patients,
especially those in advanced stages, with tumors expressing high levels of ER are
unresponsive to endocrine therapy; and all patients with advanced disease eventually
develop resistance to the therapy (19). An urgent issue is the discovery of prognostic
methods to identify those patients who need additional adjuvant therapy, such as signal
transduction inhibitors or chemotherapy, for ER-positive early breast cancer (19, 48, 49).
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The regulation of the cellular level of ERα is key to the effectiveness of endocrine
therapies in breast cancer, and an understanding of its underlying mechanism is critical
for the identification of novel drug targets for the design of combinatorial therapies (6).
Treatment options for tumors rendered positive for ER include drugs such as selective
ER modulators/antiestrogens (such as tamoxifen) and aromatase inhibitors, which are
quite effective and have relatively few side effects (6). Over the last 30 years, tamoxifen
has been the antiestrogen of first choice (4, 50, 51). However, about half of the
recurrences in ER-positive breast cancer do not respond to tamoxifen (4, 50, 51). This is
due to either acquired resistance or to intrinsic insensitivity to tamoxifen (4). From
experimental studies, many different mechanisms have been suggested to explain
resistance, including activation of kinase pathways or inactivation of retinoblastoma
protein (pRb), a tumor suppressor protein that is dysfunctional in breast cancer (4).
These changes in activation render the tumor cell independent of the ER pathway for its
proliferation (4). Tamoxifen stimulates the growth of osteoblasts (bone formation),
while it inhibits ERα-positive breast tumor cells (4). These two opposing effects of
tamoxifen on cell growth can be explained by the fact that tamoxifen is a partial
antagonist, acting as an agonist under particular conditions (4, 52). Tamoxifen resistance
is often attributed to a direct effect on ERα; tamoxifen may acquire agonistic properties
for transactivation of ERα (4, 12). Therefore, a molecular understanding of the
underlying mechanism of tamoxifen resistance could result in markers that specify how
a patient will respond to endocrine therapy (4).
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Another cell cycle regulator is cyclin D1, which forms a complex with other
regulatory subunits whose activity is required for G1/S transition in the cell cycle. In
breast cancer cells, cyclin D1 protein is often upregulated (5). It can function as a bridge
and recruit steroid receptor coactivators to the ER and stimulate transcriptional
activation in the absence of estrogen (5). The binding of cyclin D1 to the ERα promoter
increases expression because BRCA1 (breast cancer 1, early onset), a repressor of ERα
transcription, is unable to bind when the promoter is occupied by cyclin D1 (5). ERα is
lost in a breast cancer cell line by direct binding of a transcription factor, Snail – a
repressor of E-cadherin, with DNA-regulatory regions along the ERα promoter (5). Loss
of ERα signaling leads to altered transforming growth factor β (TGF-β) signaling in that
breast cancer cell line (5). TGF-β regulates cell growth, therefore altering this signaling
contributes to breast cancer.
Two current hypotheses exist to explain the relationship between breast cancer
and estrogen (1,53). The first, binding of estrogens to the ER stimulates proliferation of
mammary cells, increasing the target cell number within the tissue, and the increase in
cell division and DNA synthesis elevates the risk for replication errors (1). This may result
in the acquisition of the detrimental mutations that disrupt normal cellular processes
such as apoptosis, cellular proliferation, or DNA repair (1).
In the second hypothesis, estrogen metabolism leads to the production of
genotoxic by-products that could directly damage DNA, again resulting in point
mutations (1). There is evidence that estrogen may act through both mechanisms to
initiate and/or promote mammary cancer (1). Several sequence variations or single-
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nucleotide polymorphisms (SNPs) in the ERα gene (ESR1) have been identified that are
associated with either an increased or decreased risk of breast cancer (1). The bestcharacterized SNPs of ESR1 are the PvuII and XbaI restriction site polymorphisms, both
of which are located in the first intron (1, 54, 55). The PvuII is associated with increased
breast cancer risk, as well as risk for other diseases in which estrogen is implicated (1,
56). Both cell culture and animal model studies indicate that the ER is involved in the
mammary gland development and mammary cancer (1). Studies in ERα knockout mice
demonstrate that ERα is required for normal mammary gland development (1, 57).
Exploring the effects of phosphorylation on Ser 118 and Ser 167 has led to an
increase or decrease in overall survival. Murphy et al. (19, 38) reported that in 45
human breast tumor biopsies, phosphorylation of ERα Ser 118 correlated with active
MAPK-ERK1/2. Because MAPK-ERK1/2 is located downstream of human epidermal
growth factor receptor 2 (HER2), it is possible that phosphorylation of ERα Ser 118 is in
part caused by HER2-MAPK-ERK1/2 signaling in breast cancer (19). On the other hand,
phosphorylation of ERα Ser 167 seems to be controlled by different mechanisms (19).
Phosphorylation of Ser 118 and Ser 167 was previously analyzed using
immunohistochemistry (IHC) in primary breast tumor specimens from 75 metastatic
breast cancer patients who received first-line treatment with endocrine therapy on
relapse (19, 42). The results indicated that patients whose primary breast tumors
showed high phosphorylation of Ser 167, but not Ser 118, responded significantly to
endocrine therapy and had a better survival than other patients, suggesting that
phosphorylation of Ser 167 frequently occurs via estrogen-dependent signaling in
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human breast cancer (19). The study concluded that for the first time it has been
demonstrated that low phosphorylation of Ser 118 and high phosphorylation of Ser 167
affects survival in ER-positive breast cancer and could be helpful in distinguishing
patients who are likely to benefit from endocrine therapy alone from those who are not
(19).

Transcription and Ubiquitination

The regulation of gene expression by transcription via nuclear receptors such as
ERα is critical because it controls the phenotypic properties and diverse biological
functions of target cells. This regulation is conducted in two ways, classical and indirect.
In the classical way, an estrogen-bound ER dimerizes (forms the protein structure), binds
to the ERE, and transcribes the gene that lies within its proximity (4). The ER can also
regulate transcription of genes in an indirect manner by binding to other transcription
factors: AP1, SP1, or activated NFkB (4). When these interactions occur, transcription of
the AP1, SP1, or NFkB-dependent genes also becomes dependent on ERα (4). The
indirect method involves the receptor interacting with other transcription factors to
bind DNA by tethering to regulate target gene expression (3).
Co-repressors and coactivators function widely in transcriptional regulation (5).
Recent evidence suggests that the recruitment of coactivators and co-repressors to the
promoter of ER target genes can be affected by the binding of estrogen (ligand),
antiestrogens, and the ERE along the DNA (5). The co-repressors repress gene
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transcription by blocking access of other factors to DNA regulatory regions (5). They
operate by recruiting histone deacetylases (HDACs), allowing them to bind more tightly
to DNA, and interfere with transcriptional initiation (5). Activation of one receptor can
trans-repress the activity of another receptor by depleting a common coactivator pool,
and overexpression of these limiting factors can reverse this trans-repression or
squelching phenomenon (59, 60, 61, 62).
In contrast, nuclear receptor coactivators (NRCoA) are molecules that interact
with ligand-bound nuclear receptors and serve to facilitate the efficient transcriptional
regulation of target genes (59, 63, 64, 65, 66, 67, 68, 69, 70). Histone acetyltransferase
(HAT) adds acetyl groups to DNA, allowing the histones to unbind and leaving the DNA
free for transcription. HAT activity was the first enzymatic activity attributed to
coactivators (59). It has been proposed that coactivators are able to enhance gene
transcription either by acting as a bridge between the activated nuclear receptor and
general transcription factors (GTFs) and/or as catalytic enzymes, which may covalently
modify histones, GTFs, receptors, coactivators, and other proteins (59). The SR
coactivators have been shown to contain HAT activity that may contribute to their
ability to enhance receptor-mediated gene transcription (59). Recently, ATPase,
methyltransferase, and ubiquitin-conjugation and ubiquitin-ligase activities have also
been detected in coactivators (59). Furthermore, it has been proposed that when
assembled at the promoter of hormone-responsive genes, the concert of HAT,
methyltransferase, ATPase, and bridging activities contributed by coactivators stimulate
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transcription through nucleosome remodeling and/or covalent modification of other
components of the transcriptional complex (59).
Ubiquitination is a PTM where ubiquitin is attached to a substrate protein
and can affect proteins in many ways. These affects include signaling for the cells’
degradation via the proteasome, altering their cellular location, affecting their activity,
and promoting or preventing protein interactions. This pathway is the major system in
eukaryotic cells for selective degradation of short-lived regulatory proteins, such as ERα,
controlling the levels of target proteins and/or compositions of multiprotein complexes
in cells by targeted protein degradation (59). During the ubiquitin-proteasome pathway,
the highly conserved 76-amino acid ubiquitin protein is covalently attached to target
proteins, which are then degraded by the 26S proteasome (59).
The conjugation of ubiquitin to target proteins involves three consecutive steps
mediated by activities of the sole E1 ubiquitin-activating enzyme (UBA), multiple E2
ubiquitin conjugating enzymes (UBCs), and multiple E3 ubiquitin-protein ligases (UBLs),
respectively (59) (Appendix C). The initial step activates ubiquitin via the UBA enzyme in
an ATP-dependent reaction. The next step maintains the high-energy linkage by
transferring ubiquitin from the UBA enzyme to any one of a number of UBC enzymes
(59). Finally, UBC enzymes transfer ubiquitin covalently to target proteins either directly
or in conjunction with a UBL enzyme that defines target specifically (59). This occurs
when the first ubiquitin molecule binds to the ε-amino group of lysine residues of the
target protein (59). In succeeding reactions, a polyubiquitin chain is synthesized by
transferring activated ubiquitin to lysine of the ubiquitin moiety previously linked to the
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target protein (59). Finally, the polyubiquitinated target protein is degraded by the 26S
proteasome, a large multisubunit protease that resides both in the nucleus and
cytoplasm (59).
SRs action can be limited through the ubiquitination process, where the
receptors can be ubiquitinated, exported to the cytoplasm, and undergo proteasomemediated degradation (3). NRCoA was originally thought to exist based upon the fact
that the different receptors compete for a limited pool of accessory proteins that are
required for maximal gene transcription (59). However, recent identification of the
ubiquitin-proteasome pathway components as coactivators link this pathway to nuclear
receptor-mediated gene transcription (59). These studies demonstrate that the
ubiquitin-conjugating enzyme, UBC9, the E3 ubiquitin-protein ligases, E6-associated
protein (E6-AP) and receptor potentiation factor 1/reverse Spt phenotype 5
(RPF1/RSP5), interact with nuclear receptors and modulate their transcriptional activity
(59).
The coactivators of the ubiquitin-protease pathway are arranged in different
places along the ubiquitin-proteasome protein degradation system, harboring enzymatic
activities such as ubiquitin conjugation, ubiquitin-protein ligation, and ATPase activities
(59). There are two possibilities regarding how the enzymes operate in transcriptional
activity. The first is the enzymes of the ubiquitin-proteasome pathway exert a positive
effect on transcription by promoting degradation of negative regulators of gene
transcription (59). The second, these enzymes may be employed in the obligate
turnover of positively acting factors such as receptors, GTFs, and coactivators (59).
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Consistent with the second possibility, estrogen receptors, along with progesterone,
glucocorticoid, retinoid, and thyroid receptors are ubiquitinated and degraded through
the ubiquitin-proteasome pathway (59).
Ubiquitin-proteasome activity was shown to be required for the transcriptional
activities of most members of the nuclear hormone superfamily, but not other
nonnuclear receptor transcription factors (59). Furthermore, RNA polymerase II has also
been shown to be ubiquitinated, indicating that protein turnover is an integral part of
gene transcription (59). Microscopic analysis has also revealed the presence of
proteasome subunits at the loci of hormone-responsive genes (59). These observations
all imply that ubiquitin-proteasome-mediated protein degradation is an important
component in eukaryotic gene transcription (59).
The process of proteasomal-mediated ubiquitination is illustrated in the cellular
turnover of ERα and the identification of S-phase kinase-associated protein 2 (Skp2) (6).
Skp2 is an F-box protein (FBP) and a substrate recognition component of the Skip, Cullin,
F-box (SCF) ubiquitin ligase complex, which is overexpressed in many cancers, including
breast cancer (6). The protein functions as a novel E3-ubiquitin ligase that regulates
ubiquitination and the turnover of ERα upon specification by the p38 mitogen-activated
protein kinase (p38MAPK)-mediated phosphorylation of the receptor while positively
regulating the functional activity of this receptor (6). Scientists have observed that ERα
and the E3 ubiquitin ligase Skp2 appear to be inversely correlated (6). This concept was
confirmed while observing the half-life of ERα which was shortened from 4 hours to 45

~ 20 ~

min with overexpressed Skp2, implying SCFSkp2 E3-ligase to be a regulator of ERα protein
turnover (6).
T Cells

T cells, also called T lymphocytes, are an integral part of the immune system.
Peripheral autoimmune T cells recognize dominant self-antigens, which is a property of
all healthy immune systems. The number of T cells is indicative of a healthy individual
and a count that is too low or too high is a sign of a disease, such as HIV or lupus.
Human T cells express both ER subtypes, and the use of receptor-specific ligands
indicates that the receptors are functional (17, 71). Furthermore, it had been shown
that estrogen increases two markers of T-cell activation (17, 72, 73).
Protein kinase C (PKC) is a family of enzymes involved in controlling the
function of other proteins through the phosphorylation of amino acid residues on these
proteins. PKC is thought to be the mediator of the phosphorylation events that occur
after treatment of cells with phorbol 12-myristate 13-acetate (PMA) (74). This occurs in
conjunction with ionomycin, which is used to raise the intracellular level of calcium.
The cluster of differentiation (CD3) T cell co-receptor is a protein complex
composed of four distinct chains. The chains associate with a molecule known as the T
cell receptor (TCR) to generate activation signal in T lymphocytes. Stimulation of T cells
with antibodies to the CD3/T-cell receptor complex causes turnover of
phosphatidylinositol to form inositol trisphosphate (IP3) which can mobilize calcium
from cytoplasmic stores (74). Diacylglycerol (DAG) is a second messenger molecule used

~ 21 ~

in signal transduction and lipid signaling in biological cells. It is a product of the
phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) by the enzyme phospholipase
C (PLC), which produces IP3 in the same reaction.
This signal transduction pathway can lead to T-cell activation when other
required signals are provided by accessory cells: interleukin 1, a group of 11 cytokines
which plays a central role in the regulation of immune and inflammatory responses; as
well as anti-Tp44 and anti-CD5 monoclonal antibodies (Mabs), which bind to the antigen
on the surface of the T cell protein (74). The increase in cytoplasmic Ca2+ in normal T
cells after anti-CD3 stimulation was sensitive to inhibition by pertussis toxin, supporting
the conclusion that this activation pathway relies on phospholipase C-dependent
formation of IP3 and DAG (12).
There is evidence that anti-CD3 causes cytoplasmic calcium levels to increase
through two mechanisms: to control a membrane potentially sensitive calcium gate and
to cause mobilization of cytoplasmic calcium through PKC-mediated hydrolysis of PIP2
(74). The calcium increase after CD3 stimulation was only partially inhibited by ethylene
glycol tetraacetic acid (EGTA) (related to EDTA), which binds to calcium and prevents
adjoining of cadherins; but was totally inhibited by pertussis toxin (74). Pertussis toxin
ribosylates (attaches a ribose or ribosyl group to a molecule) and thus inactivates Gi
(inhibits the production of cAMP from ATP) and other GTP-binding proteins (G proteins)
that regulate signal transduction, including phospholipase C activation in neutrophils
(74).
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While CD3 activates T cells, T cells themselves can activate different cell signaling
pathways, such as MAPK-ERK1/2 signal transduction pathway through the stimulation of
T cells with antibodies against the T cell receptor complex. Anti-CD3 antibody and PMA
activate MAPK signaling through ERK1/2 and affect T-cell responsiveness by altering the
levels of transcription factor activity (17). MAPK-ERK1/2 signaling controls enzymes that
modulate DNA methylation which in turn exerts direct effects on gene expression (17).
The altering of target gene transcription also occurs when estrogen binds to its
receptors. However, estrogen can also act through the plasma membrane and rapidly
stimulate second messengers including calcium flux and kinase activation (17, 75). ERK
activation by estrogen has been reported in tumor cell lines, vascular endotheium and
osteocytes (17). The importance of this rapid signaling at the plasma membrane for
subsequent cell function has been shown by increased proliferation, survival and
migration of target cells (17).

Abnormalities – Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune
disease characterized by multiple organ damage, high titers of antibodies, and various
clinical manifestations (76). The characteristic manifestation is the butterfly rash that
erupts on the cheeks of the face. SLE affects an estimated 1.5 million people in the
United States, with 16,000 new cases reported every year. Of those cases, there is a 1015 times higher frequency of SLE in women during childbearing years, probably due to
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an estrogen hormonal effect; and several studies have suggested that gender
differences in lupus susceptibility are mediated by sex hormones, consistent with the
fact that 90% of SLE sufferers are females (76). Furthermore, there is an increased risk
of developing SLE in postmenopausal women who received estrogen hormone
replacement therapy (76).
It is well established that ERs stimulate the proliferation of a variety of cell types
including cells belonging to the immune system (5). Estrogen is found to be a potential
contributor to the development of biased autoimmune disease, such as SLE (5).
Overexpression of cell-cycle-regulatory proteins may lead to abnormal estrogendependent gene regulation (5). ERα is an epigenetically regulated gene, and T cells from
SLE patients have decreased total genomic methylation compared with age-matched
controls, predicting an increase on transcription. This is consistent with a report
suggesting ERα transcripts are higher in circulating T cells of SLE patients compared with
normal T cells (5). This is reversed at the protein level, however, where ERα is lower in
the T cells of some SLE patients compared with the amount of T cells from normal
individuals (5).
Low ERα levels in SLE T cells could result from increased turnover in the protein,
in which protein degradation via the ubiquitin-proteasome system has emerged as a
major regulator of nuclear receptor transcription (5). The 20S proteasome β subunit low
molecular mass polypeptide 2 (LMP2) is necessary for ER-dependent transcription and
cell-cycle progression (5). It is thought that inappropriate assembly and turnover of the
ERα complex could underpin the aberrant estrogen-dependent gene regulation (5). This
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could contribute to global deregulation of gene expression, since SLE T cells are known
to be deficient in protein phosphorylation (5). Results suggest that the T cells from SLE
patients with inactive or mild disease respond to estrogen by suppressing
phosphorylation, but as disease activity increases, the suppressive effect is lost (5).
The primary cause of disease onset is suggested to occur from defects in T cellmediated signaling that leads to hyper-responsive B cells, increased cytokine production
and the breakdown of immunological tolerance (17). Estrogen increases the production
of cytokines and immunoglobulins in circulation, and is reported to enhance the
proliferation of T cells and macrophages and to directly stimulate the expression of
genes in mouse B cells that allows some autoreactive cells to escape apoptosis (5).
Cytokine networks have been studied in pregnant women, and are found to be
involved in sex hormones. These networks regulate the level of sex hormones both
systematically and locally, especially in the reproductive organs (76). There are two
types of cytokines that estrogens mediate: T helper type 1 (Th1) and T helper type 2
(Th2). Estrogens inhibit cell-mediated immune response via Th1 cytokines and induce
antibody production via Th2 cytokines. Low levels of estrogens and interleukin-6 (IL-6)
are thought to be responsible for low activation of the humoral immune response,
which then leads to the lower disease activity observed over the same period in SLE
patients (76). This is suggested from research preformed on SLE patients and healthy
controls in their third trimester of pregnancy, which found that IL-6 progressively
increases in maternal circulation in healthy individuals during pregnancy, but low levels
of IL-6 have been reported during the third trimester of pregnancy in SLE patients (76).
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Proposed Project

The intent of this research was to identify whether there are alterations on three
specific phosphorylation sites (Ser 104/106, Ser 118, Ser 167) of the ERα between
resting and activated T cells. Based on previous work conducted in the laboratory, we
know that the MAPK-ERK1/2 pathway phosphorylates T cells, and the pathway is
abnormal in SLE T cells. The purpose of this study was to see if there were differences in
the three sites in healthy volunteer women to get a baseline before conducting this
study on SLE patient.
The research was conducted by analyzing ERα in human T cell extracts using
phospho-specific antibodies and chemiluminescent detection on Western blots.
Statistical analyses was completed to show the significance in the changes of
phosphorylation.
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CHAPTER II

MATERIALS AND METHODS

Study Participants
Person

Age

Ethnicity

Estradiol/Estrogen
Levels (pg/mL)

1

22

Caucasian

298.45

2

22

Caucasian

313.44

3

36

Caucasian

112.14

4

32

Caucasian

267.67

5

35

Caucasian

300.72

6

18

African American

309.23

7

23

Indian

124.61

8

27

Indian

334.38

9

20

Caucasian

161.36

10

19

Caucasian

160.01

Table 1

~ 27 ~

Table 1. The study participants were 10 healthy female volunteers. It was important that
they were not on birth control that regulated their estrogen hormone levels and had a
regular menstrual cycle. There was no age requirement as long as they had regular
menstrual cycles and their estradiol were in the normal range. The plasma
estradiol/estrogen levels showed to be within the normal range for women with regular
menstrual cycles.

T Cell Separation

80 mls of blood was drawn from the female control volunteers 0sing BD
Vacutainer K2 EDTA (K2E) Plus Blood Collection Tubes and diluted about 1:1 with 1X PBS
(phosphate buffered saline), making sure the tubes were mixed well before collecting
and after diluting. The diluted blood was layered over 12 ml of Histopaque 1077 and
centrifuged for 20 minutes in a centrifuge at 1600 rpm at 22°C. Plasma (1.5 ml) was
collected for future use, stored at -80°C, and the rest of the platelets and most of the
medium was discarded. The white blood cell layer was carefully collected into a clean
tube and the volume was brought up to 50 ml with medium (1X PBS). The cells were
washed at 1900 rpm for 10 minutes and the medium was poured off. The pellet was
resuspended and 10 ml of medium was added. The volume was brought up to 30 ml
with medium and washed again before being centrifuged at 1600 rpm for 10 minutes
and the wash medium was poured off. While the cells were being centrifuged, lysis
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buffer was prepared by adding 1 ml of H-Lyse buffer into 9 ml of sterile water and
mixing well. Lysis buffer (10 ml) was added to the cells and incubated at room
temperature for 10 minutes. The ammonium chloride in the solution disrupted the
osmolality of the red blood cells (RBCs) but not the T cells, causing lysis of only the RBCs.
The volume was brought up to 50 ml with 1X wash buffer and centrifuged the cells at
1900 rpm for 10 minutes.
The R&D System Human T Cell Enrichment Column allows for negative selection
of CD3+ T cells. The column has mononuclear cell suspensions, which allow for B cells
and monocytes to bind to glass beads coated with anti-Ig and Ig respectively. The
column was prepared by equilibrating the column and the 1X Column Wash Buffer at
room temperature. After it was at 22°C, the column was placed in the column rack
before removing the top cap followed by the bottom cap. The fluid in the column was
allowed the drain into a waste receptacle before the column was washed with 6 ml of
Column Wash Buffer. Once the column had been washed, the waste receptacle was
replaced with a sterile 15 ml polypropylene tube. After cells are centrifuged, the wash
and lysis buffer was poured off and the cell pellet was resuspended in 1 ml of column
Wash Buffer. The cell suspension was added to the column and the filter was removed
for proper draining. Once the cells had drained down to the white filter, they were
incubated at room temperature for 10 minutes. The cells were eluted from the column
using 4 aliquots (2 ml each) of Column Wash Buffer. The collected T cells were
centrifuged at 250 xg for 5 minutes. The T cells were now pure and ready for use. The
cells were either activated for 4 hours or lysed and stored at -80°C.
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Pharmacological Activation of Human T Cells

The T cells were activated by the addition of phorbol 12-myristate 13-acetate
(PMA) at 1 mg/ml in sterile dimethyl sulfoxide (DMSO). The stock was diluted 1:100 so
10 µl of stock was added to 990 µl of serum free culture medium with glutamine to
make 10 µg/ml. Stock (1 µl) was added to 1 ml of culture medium for a final
concentration of 10 ng/ml.
For the ionomycin, the stock was made up of 1 mg/ml in sterile culture medium
or RPMI medium. The stock was diluted 1:10 for a concentration of 0.1 µg/µl.
Ionomycin (5 µl) was added per ml of serum free medium with glutamine for a final
concentration of 0.5 µg/ml. PMA and ionomycin enhance the activation of PKC and
causes an influx of Ca2+.

Immunoprecipitation Using Antibodies and Protein A/G PLUS Slurry

After the T cells were either activated or the resting T cells were pelleted, they
were resuspended in 1 ml of PBS and transferred to 1.5 ml eppendorf tube. The tubes
were centrifuged at 8000 rpm for 5 minutes and the medium was removed before 500
µl of lysis solution (10 mM tris-HCl, pH 7.5, 30 mM sodium pyrophosphate, 50 mM
sodium chloride, 50 mM sodium fluoride, 5 mM EDTA, 1% Triton x-100, 1 mM sodium
orthovnadate) was added and the cells were resuspended. The tube was placed on ice
for 30 minutes before it was centrifuged for 10 minutes in a microcentrifuge at 4°C at
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2,500 rpm to get rid of cellular debris. The protein was transferred to a fresh tube on ice
and the concentration was determined using a NanoDrop Lite Spectrophotometer. This
worked by placing 2 µl of the sample onto the metal plate after blanking and selecting
the protein µg/µl. It quantifies the concentration by wavelengths, in which different
wavelengths give different concentrations. In this case, the spectrophotometer read the
absorbance of the protein at 280 nm wavelength. The µl needed for 100 µg of protein
was obtained by dividing 100 by the number it gave you from the spectrophotometer.
Protein (100 µg) was combined into a chilled Eppendorf and volume was brought up to
100 µl with lysis solution.
ERα antibody (1 µl) was added to the Eppendorf tube and nutated at 4°C for 1
hour (Appendix D). Protein A/G PLUS slurry (20 µl, Santa Cruz, sc-2003) was added to
the tube and left overnight on the nutator. The tubes were centrifuged at 2,500 rpm for
5 minutes at 4°C, and the supernatant was removed into a fresh tube and saved. The
tubes were washed 3 times with 1 ml of PBS-0.1 M NaCl each time and microcentrifuged
at 2,500 rpm for 5 minutes at 4°C between washes, with the supernatant removed each
time.

Western Blot

Making the gel
The lower gel was made by adding 11.9 ml of distilled water to 10 ml of 30%
acrylamide, then 7.5 ml of lower gel buffer (4x). Sodium dodecyl sulfate (SDS, 10%, 300
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µl) and 300 µl of ammonium persulfate (10%) was added to the beaker or flask.
Tetramethylethylenediamine (TEMED, 30 µl) was placed in the solution and poured in
between two plates that have been cleaned with detergent and ethanol. A thin layer of
water was added to the top of the layer to aid in polymerization. The gel was set aside
for 15 minutes to ensure polymerization. Once the layer has polymerized, the water was
discarded and the upper gel was ready to be added.
The upper gel was made by adding 3 ml of 30% acrylamide to 11.7 ml of distilled
water, followed by 5 ml of upper gel buffer (4x). SDS (200 µl, 10%) and 200 µl of
ammonium persulfate (10%) were added to the flask. TEMED (20 µl) was placed in the
flask or beaker and the solution was poured on top of the lower gel. The comb was
added and the gel aside was set for an hour to polymerize completely. After the gel had
set up, it was placed in an apparatus where 1X reservoir buffer was added to the
chamber.

Preparing the samples

After the samples had been washed with PBS-0.1 M NaCl 3 times and the sample
dye (2 ml of 1 M Tris—HCl at a pH of 6.8, 4.6 ml of 50% glycerol, 1.6 ml of 10% SDS, 0.4
ml of 0.5% bromphenol blue, and 0.4 ml of β-mercaptoethanol) was added, the samples
were heated at 95°C for 5 minutes and centrifuged for 30 seconds to one minute at
16,873 xg. The Precision Plus Protein Kaleidoscope molecular weight ladder and the
samples were added to the desired wells and the apparatus was attached to a power
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source where 60 volts was applied until the samples had left the wells, once that
happened it was turned up to 100 volts. The gel ran for 3 to 4 hours or until the dye had
reached the bottom of the lower gel.

Membrane Transfer

The plates were disassembled from the apparatus and one glass plate was
removed. The gel was soaked in Transblot buffer for 5 minutes on the plate before a dry
Whatman no. 2 filter paper, cut to the size of the Scotchbrite pad, was placed onto the
gel. The paper was rubbed to adhere gel to paper and the filter paper was peeled back
along with the gel. The nitrocellulose sheet was prewet in the transblot buffer (2 M Tris
pH 8.3, glycine, methanol, 10% SDS, deionzed water) and placed onto the gel, and with a
gloved hand,air bubbles trapped between the gel and filter were rubbed out. The
molecular weight markers were marked with a pen and a prewet Whatman filter paper
the size of the pads was placed on top of the nitrocellulose before any air bubbles were
rubbed out. The Whatman filter sandwich was closed into the gel holder and placed into
the electrophoresis tank that was filled with transblot buffer. The tank was attached to a
power supply and set at 12 volts where it was left overnight.
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Chemiluminescent Detection of the Receptor

ER-α
The membrane was blocked for 1 day in 100 ml of Super Block Buffer (Thermo
Scientific 37517) containing 500 µl 10% Tween. Afterwards, the membrane was reacted
for 1 hour with shaking using 8 ml of a primary antibody (ER-α Santa Cruz MC-20) at a
1:1000 dilution. This was done by taking 8 µl of ER-α and placing it in 8 ml of block
buffer. The membrane was placed in a sealed bag and the primary antibody was added
before the end was sealed. The membrane was wash 4 times for 5 minutes eachin
approximately 200 ml of Wash Buffer containing 5 ml of 10% tween in 1 liter of PBS.
Afterwards, the membrane was incubated for 1 hour with shaking in 8 ml of secondary
antibody specific for rabbit antibodies at 1:4000 dilution. This was done by taking 2 µl of
goat anti-rabbit antibody (Thermo Scientific 32460) and placing it in 8ml of block buffer.
The membrane was placed in sealed bag just like for the primary antibody. After one
hour it was washed again the same way as the primary wash. The blot was incubated
with a SuperSignal West Femto Maximum Sensitivity Substrate kit, using 5 ml Luminol
solution and 5 ml of horseradish peroxidase buffer, measured in a small graduated
cylinder and inverted to mix. The bag was placed on shaker for 5 minutes. The blot was
placed in a gel documentation system for 30 seconds to 1 minute. Densitometry was
analyzed using ImageJ.
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Strip and reblock

The blot was stripped using 10 ml of stripping buffer (Thermo Scientific 21059)
and placed on the shaker for 15 minutes. It was reblocked for 1 hour or overnight and
reprobed with ER-α ser 104/106 (sc-12956), ER-α ser 167 (sc-101676), and ER-α ser 118
(sc-12915).

Statistics

The statistical analysis was conducted using a t-Test. The test compared the
mean value of total ERα to the mean values of each phospho-specific site in both resting
and activated conditions. A p value of less than 0.05 was considered to be statistically
significant.
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CHAPTER III

RESULTS

Experimental Control

The T47D cell line (85102201 SIGMA) was used as the positive control in
the Western Blots. This is a human breast tumor cell line established from the pleural
effusion of a ductal carcinoma of the breast of a 54-year-old female. The cells were
grown in RPMI-1640 and glutamine, along with fetal bovine serum (FBS), pen-strep
(penicillin streptomycin), and bovine insulin (insulin from bovine pancreas, SigmaI6634). When the cells were first taken out of the liquid nitrogen, they were placed in
20% FBS, then after a day the cells were switched to 10% FBS and grown until the
desired number was used or refrozen. The positive control helped establish errors in the
technique of the blots early in the process.

Activation with PMA and Ionomycin

The extracted T cells were divided into two groups, resting and activated.
The rationale behind activating half of the cells and determining if there was a
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difference between the two groups was due to the fact that T cells are activated
through the ERK pathway, which is known to be part of the immune process. This
simulated how the cells would change in phosphorylation during an immune response
or deficiency such as SLE. The T cells were extracted and activated with PMA (10 ng/ml)
and ionomycin (0.5 µg/ml) for 4 hours.

The Ratio between ERα and the Phospho-Specific Sites in Resting and Activated T Cells

Early work (Table 2) shows the progression of technical skills and new
antibody troubleshooting. The ratio data was accomplished from a gel documentation
system instead of X-ray film like blots shown in early work. Tables 3-6 illustrate the
phosphorylation of the four antibodies in resting T cells, while Tables 7-10 show the
activated T cells in response to the four antibodies.
An analysis was performed on the blots using Image J and the mean value
was collected from each phosphorylation for both resting and activated. Each phosphoantibody was divided by ERα to get a percentage in the amount of phosphorylation for a
particular site compared to the entire receptor. In the resting T cells (Table 11), ERα Ser
104/106 was found to have the highest amount of phosphorylation and ERα Ser 118 had
the lowest. This differed when the T cells were activated (Table 12), where again ERα
Ser 104/106 had the highest amount of phosphorylation, but ERα Ser 167 had the
lowest. Finally the mean values were graphed and standard error was added (Figures 1
and 2).
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Measurement of Plasma Estradiol/Estrogen

The plasma estradiol levels were measured to ensure the estradiol in plasma
from the control females were within normal range. The normal levels of estradiol range
between 30 to 400 pg/ml. The range is broad because the level varies in time and is
dependent on the woman’s menstrual cycle. During the follicular phase, the levels range
from 19 to 140 pg/ml. It increases during the preovulatory peak around 110 to 410
pg/ml. The range falls between 19 to 160 pg/ml during the luteal phase. It was
important to make sure the women used in the study were within normal range since it
was the hormone of interest.
Plasma was collected at the time of blood draw. Samples were analyzed by EIA
using a kit ALPO (11-ESTHU-E01). The coefficient of variation was 5.85% across all
samples (Table 1). The assay was conducted at the Kansas Intellectual and Development
Disabilities Research Center at the University of Kansas Medical Center.

Statistics

The t-test found that for ERα Ser 118 and ERα Ser 167 in both resting and
activated, the values were statistically significant with a p = 0.006 for resting ERα Ser
118, p = 0.048 for activated ERα Ser 118, p = 0.050 for resting ERα Ser 167, and p = 0.05
for activated ERα Ser 167. However, for ERα Ser 104/106 in both resting and activated,
values were found not to be significant.
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Data Used for Analysis

Samples
ERα

1

2

3

4

5

6

7

8

9

10

Resting
ERα
Resting
ERα
Resting

Table 2
Table 2. Western blots of phosphorylated ERα in resting T cells. The 10 resting T cell
samples in duplicate were reacted with the primary ERα antibody at a 1/1000 dilution
before adding the secondary goat anti-rabbit antibody at a 1/4000 dilution. The
phosphorylated ERα migrated to 66 kDa.
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Table 3
Table 3. Western blots of phosphorylated ERα Ser 104/106 in resting T cells. The 10
resting T cell samples in duplicate were reacted with the primary ERα antibody at a
1/1000 dilution before adding the secondary goat anti-rabbit antibody at a 1/4000
dilution. The phosphorylated ERα Ser 104/106 migrated to 66 kDa.
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Samples
ERα Ser
118
Resting

1

2

3

4

5

6

7

8

9

10

ERα Ser
118
Resting
ERα Ser
118
Resting

Table 4
Table 4. Western blots of phosphorylated ERα Ser 118 in resting T cells. The 10 resting T
cell samples in duplicate were reacted with the primary ERα Ser 118 antibody at a
1/1000 dilution before adding the secondary goat anti-rabbit antibody at a 1/4000
dilution. The phosphorylated ERα Ser 118 migrated to 66 kDa.
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Samples
ERα Ser
167
Resting

1

2

3

4

5

6

7

8

9

10

ERα Ser
167
Resting
ERα Ser
167
Resting

Table 5
Table 5. Western blots of phosphorylated ERα Ser 167 in resting T cells. The 10 resting T
cell samples in duplicate were reacted with the primary ERα Ser 167 antibody at a
1/1000 dilution before adding the secondary goat anti-rabbit antibody at a 1/4000
dilution. The phosphorylated ERα Ser 167 migrated to 66 kDa.
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Table 6
Table 6. Western blots of phosphorylated ERα in activated T cells. The T cells were
activated in PMA (10 ng/ml) and ionomycin (0.5 µg/ml) for 4 hours. The 10 activated T
cell samples in duplicate were reacted with the primary ERα antibody at a 1/1000
dilution before adding the secondary goat anti-rabbit antibody at a 1/4000 dilution. The
phosphorylated ERα migrated to 66 kDa.
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Table 7
Table 7. Western blots of phosphorylated ERα Ser 104/106 in activated T cells. The T
cells were activated in PMA (10 ng/ml) and ionomycin (0.5 µg/ml) for 4 hours. The 10
activated T cell samples in duplicate were reacted with the primary ERα Ser 104/106
antibody at a 1/1000 dilution before adding the secondary goat anti-rabbit antibody at a
1/4000 dilution. The phosphorylated ERα Ser 104/106 migrated to 66 kDa.
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Table 8
Table 8. Western blots of phosphorylated ERα Ser 118 in activated T cells. The T cells
were activated in PMA (10 ng/ml) and ionomycin (0.5 µg/ml) for 4 hours. The 10
activated T cell samples in duplicate were reacted with the primary ERα Ser 118
antibody at a 1/1000 dilution before adding the secondary goat anti-rabbit antibody at a
1/4000 dilution. The phosphorylated ERα Ser 118 migrated to 66 kDa.
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Table 9
Table 9. Western blots of phosphorylated ERα Ser 167 in activated T cells. The T cells
were activated in PMA (10 ng/ml) and ionomycin (0.5 µg/ml) for 4 hours. The 10
activated T cell samples in duplicate were reacted with the primary ERα Ser 167
antibody at a 1/1000 dilution before adding the secondary goat anti-rabbit antibody at a
1/4000 dilution. The phosphorylated ERα Ser 167 migrated to 66 kDa.
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ERα

ERα Ser 104/106

ERα Ser 118

ERα Ser 167

100%

89%

80%

86%

Mean Expression
Percentage

Table 10
Table 10 The percentage of phosphorylation of ERα and three sites compared with total
ERα in the same samples. Data and mean values from 10 resting T cell samples in
duplicate.

ERα

ERα Ser 104/106

ERα Ser 118

ERα Ser 167

100%

92%

88%

78%

Mean Expression
Percentage

Table 11
Table 11 The percentage of phosphorylation of ERα and three sites compared with total
ERα in the same samples. Data and mean values from 10 activated T cell samples in
duplicate.
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8.0000
7.0000

Mean Expression

6.0000
5.0000
4.0000
3.0000
2.0000
1.0000
0.0000

ERα

ERα Ser 104/106

ERα Ser 118

Phosphorylation Site

ERα Ser 167

Figure 1
Figure 1 The greatest amount of phosphorylation was in ERα Ser 104/106, while the
least amount of phosphorylation was in ERα Ser 118. Data are mean values from 10
resting T cell samples in duplicate ± SD. The standard deviations were 1.99, 2.23, 1.26,
and 1.36 respectively.
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8.0000
7.0000

Mean Expression

6.0000
5.0000
4.0000
3.0000
2.0000
1.0000
0.0000

ERα

ERα Ser 104/106

ERα Ser 118

ERα Ser 167

Phosphoylation Site

Figure 2
Figure 2 The greatest amount of phosphorylation was in ERα Ser 104/106, while the
least amount of phosphorylation was in ERα Ser 167. Data are mean values from 10
activated T cell samples in duplicate ± SD. The standard deviations were 2.19, 2.23, 2.27,
and 1.87 respectively.
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CHAPTER IV

DISCUSSION

Western blot analysis was the main method used for studying the ERα
because it is a protein. This method separates proteins by weight and a desired protein
can be found on a gel with the addition of a size standard. Immunoprecipitation goes a
step further and allows the extraction of the desired protein with the aid of the antibody
for that protein and beads in the A/G slurry which pull the desired antibody-protein
complex to the bottom of the tube while letting all the other protein be extracted in the
supernatant. This extra step in the Western blot process grants more precise accuracy
that the band being expressed is the protein desired and not one of many in the sample.
The protein bound to the antibody is added to an acrylamide gel and a power source
separates the protein vertically down the gel. Once the protein is embedded in the gel,
it is transferred to a membrane, which allows multiple antibodies to be reacted with the
membrane.
For this project, three sites on the ERα receptor (Ser 104/106, Ser 118, and
Ser 167) were chosen to study. These sites were chosen based on a previous study
performed in the laboratory looking at the ERK pathway in SLE T cells (17). The results
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showed the response of T cells from patients with SLE to the effects of estrogen
appeared divided into two groups. Approximately one-half of the SLE T cells showed
decreased ERK ½ phosphorylation in response to estrogen (17). When the ratios of
phosphorylated ERK ½ to total ERK based on the patient’s disease activity, estrogen
significantly decreased ERK ½ activation in the T cells from women with inactive or mild
disease activity (17). The results suggest that the suppression of MAPK through ERK ½
phosphorylation is sensitive to estrogen in patients with inactive or mild disease activity,
but the mechanism was not maintained when disease activity increased (17).
The three sites were phosphorylated from T cells obtained from ten
healthy women in two conditions: resting and activated. I hypothesized that there
would be a difference in phosphorylation of the three sites in resting conditions versus
activated. Since the MAPK-ERK1/2 pathway is abnormal in lupus patients and it is
responsible for activating T cells, it is thought the expression would be lower. Since no
one has studied these particular sites in healthy individuals, a baseline needed to be
obtained to see if there is a difference in resting versus activated before exploring the
effects in SLE patients.
The results showed an increase in phosphorylation when the T cells were
activated versus resting in both ERα Ser 104/106 and ERα Ser 118, but a decrease in
resting versus activated in ERα Ser 167 (Tables 11 and 12). There was a significant
difference in two of the three sites, ERα Ser 118 and Ser 167. The results were
significant in both resting (p=0.006 and p=0.050 respectively) and activated (p=0.048
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and p=0.05 respectively). This was not the case for ERα Ser 104/106, where in both
resting and activated the results were not significant (p=0.12 and P=0.17 respectively).
Examining the results, I was not surprised by the P values. ERα Ser 118 gave the
lowest p value, followed by ERα Ser 167. On the other hand Ser 104/106 gave the
highest p value. I had to react the blot twice with the antibody with almost every
Western blot prepared. There was either too much background to begin with or the
exposure time had to be lengthened which caused more background to appear. Other
times nothing would show up on the blot. This caused the antibody to have the most
deviation in both conditions.
The estradiol/estrogen levels were obtained from serum samples in the control
volunteers’ blood to verify the levels were within the normal range given by the
laboratory that tested the samples. Estradiol is the predominant form of estrogen
during the reproductive years of a woman’s life. 17β-estradiol (estradiol) exerts
biological effects after binding to the receptors ERα and ERβ (77). The levels needed to
be within range to ensure there was enough hormone in the sample for the antibody to
bind. It also confirmed the levels were not too high.
Studying the role of estrogen and estradiol is critical to study in healthy
individuals in order to know how it changes during diseases or abnormalities of human
health. Two of the predominant diseases or abnormalities that estrogen has a role in is
SLE and breast cancer. The disorder this laboratory is focusing on is SLE.
Steroid hormones facilitate the immune response, with estrogens as enhancers
for humoral immunity (78). For SLE, estrogen are known to play an important role as a
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mediator of SLE disease onset/perpetuation (78). The role of sex hormone
concentrations at the level of inflammatory foci is valuable information needed to
explain the modulatory effects exerted by these hormones on the immuneinflammatory reaction (78). There is a correlation in SLE patients between aromatase,
the enzyme that produces estrogens, and IL-6 production, which causes inflammation.
This aromatase activity, studied in the skin and subcutaneous tissue, varies inversely
with disease activity; and furthermore, there is a significant direct correlation with
estrogen levels in SLE patents (78). In addition, findings suggest there is an accelerated
metabolic conversion of upstream androgen precursors to estrogen in SLE patents, and
estrogen recognizes upstream precursors of different hormones (78). Furthermore,
these findings may partially explain the abnormalities of peripheral estrogen synthesis in
SLE, as well as the altered serum sex hormone levels and ratio (78). Taken all together,
estrogen has a significant impact on SLE patients and finding out how this hormone
interacts with the body in healthy individuals can lead to finding how it contributes to
SLE.
Since this study has concluded that there are statistically significant
differences in phosphorylation in resting versus activated in two of the three sites for
healthy women, the next step is to test these antibodies on SLE patients. It is known
that these three sites are phosphorylated through the MAPK-ERK1/2 pathway. The
hypothesis is because the pathway is abnormal in SLE patients, there will be a greater
difference in the resting versus activated ratio. It is thought there will be a significant
change in expression of one or more of the three sites due to the abnormal MAPK-
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ERK1/2 pathway in its role in the activation of T cells. This work has created a baseline
for which the SLE patients can be compared to. If we can find there is a change in
phosphorylation in one or more of these site, it will be the first step in treating SLE by
changing one or more site on the ER without changing the entire receptor. I expect
there will be a decrease in phosphorylation in the activated T cells compared with the
controls due to the increase turnover of the T cells in SLE T cells. The loss in time
between synthesis and degradation is also a loss of time the receptor has to carry out its
action on the T cell, leading to a decrease in phosphorylation.
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ABBREVIATIONS

ABBREVIATION

WORD

AF1
AF2
AP1
BRCA1
CD3
CDK7
DAG
DBD
DMSO
E6-AP
EDTA
EGF
EGFR
EGTA
ER
ERα
ERβ
ERE
ERK1/2
FBP
FBS
G1/S
GSK3β
GTF
H
HAT
HDAC
HER2
IGF
IHC
IKKα
IL-6
IP3
K2E
LBD
LMP2
MABS
MAPK
mTOR/p70S6K
NO
NRCoA
NTD

activation function 1
activation function 2
activator protein 1
breast cancer 1, early onset
cluster of differentiation
cyclin-dependent kinase 7
diacylglycerol
DNA-binding domain
dimethyl sulfoxide
E6-associated protein
Ethylenediaminetetraacetic acid

epidermal growth factor
epidermal growth factor receptor
ethylene gycol tetraacetic acid
estrogen receptor
estrogen receptor alpha
estrogen receptor beta
estrogen response element
extracellular signal-regulated kinase 1 and 2
F-box protein
fetal bovine serum
gap 1/synthesis
glycogen synthesis kinase-3 beta
general transcription factor
hinge region
histone acetyltransferase
histone deacetylase
human epidermal growth factor receptor 2
insulin-like growth factor
immunohistochemistry
IkappaB kinase complex
interleukin-6
inositol trisphosphate
K2 EDTA
carboxyl-terminal ligand binding domain
low molecular mass protein 2
monoclonal antibodies
mitogen-activated protein kinase
mammalian target of rapamycin
nitric oxide
nuclear receptor coactivator
amino-terminal domain
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p38MAPK
p90RSK
PAK-1
PBS
PIP2
PKA
PKB
PKC
PLC
PMA
PR
RBC
pRb
PRO
PTM
RPF1/RSP5
RSK
SCF
SDS
SER
Skp2
SLE
SNP
SP1
SR

TCR
TEMED
TGF-β
Th1
Th2
Thr
Tyr
UBA
UBC

UBL

protein 38 mitogen-activated protein kinase
protein 90 ribosomal s6 kinase
protein 21-activated kinase 1
phosphate buffered saline
phospholipid phosphatidylinositol 4,5-bisphosphate
protein kinase A
protein kinase B
protein kinase C
phospholipase C
phorbol 12-myristate 13-acetate
progesterone receptor
red blood cell
retinoblastoma protein
Proline
post-transcriptional modification
receptor potentiation factor 1/reverse Spt phenotype 5
ribosomal s6 kinase
skip, cullin, F-box
sodium dodecyl sulfate
serine
S-phase kinase-associated protein 2
systemic lupus erythematosus
single-nucleotide polymorphisms
specificity protein 1
steroid receptor
T cell receptor
tetramethylethylenediamine
transforming growth factor β
T helper type 1
T helper type 2
threronine
tyrosines
ubiquitin-activating enzyme
ubiquitin conjugating enzymes
ubiquitin-protein ligases
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APPENDIX

Appendix A
Steroid receptors share a common structure of carboxyl-terminal ligand
binding domain (LBD), Amino-terminal domain (NTD), and a DNA-binding domain (DBD).
The NTD contains the hormone independent coactivator interface AF1, where the
majority of the phosphorylation sites are.
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Appendix B
A total of 19 phosphorylation sites have been identified in ERα thus far.
The majority of them are serine sites, and a few are threonines and and tyrosines.
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Appendix C
The ubiquitination pathway allows for selective degradation of short-lived
regulatory proteins, such as ERα, controlling the levels of target proteins and/or
compositions of multiprotein complexes in cells by targeted protein degradation. It
occurs in three steps: the initial step activates ubiquitin via the UBA enzyme (E1) in an
ATP-dependent reaction. The next step maintains the high-energy linkage by
transferring ubiquitin from the UBA enzyme to any one of a number of UBC enzymes
(E2). Finally, UBC enzymes (E3) transfer ubiquitin covalently to target proteins either
directly or in conjunction with a UBL enzyme that defines target specifically
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`
Appendix D
Immunoprecipitation provides better accuracy for analyzing proteins. The
first step is to add the protein to the desired antibody. After nutating for an hour, the
protein A or G coupled beads are added. While on the nutator, the beads bind to the
protein-antibody complex. The tubes are microcentrifuged, allowing the complex to be
pulled to the bottom of the tube and the other protein to be extracted.
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